Ulcerative colitis
Eli Lilly launches Omvoh for ulcerative colitis after FDA nod
Eli Lilly, known for its weight loss contender Mounjaro, is making strides in the immunology arena. The FDA has granted ...
Roche’s $7B Investment Ignites Intense Competition with Merck in the Bowel Disease Market Amid TL1A Feeding Frenzy
Roche has made a substantial move by agreeing to pay Roivant and Pfizer $7.1 billion upfront for regional rights to ...
Pfizerâs Velsipity gets FDA approval to challenge BMSâ Zeposia in ulcerative colitis market
Pfizer’s groundbreaking approval of its drug, Velsipity, as a once-daily oral treatment for adults suffering from moderate to severe active ...
Lillyâs mirikizumab shows promise in Crohnâs disease after failing in psoriasis
After a previous setback when the FDA withheld approval for mirikizumab in ulcerative colitis due to manufacturing issues, Eli Lilly’s ...
Ventyx reports positive phase 2 data for bowel disease drug, but fails to impress investors amid competition
Investors have shown skepticism toward Ventyx Biosciences’ attempt to challenge Bristol Myers Squibb and Pfizer in the ulcerative colitis market. ...
Morphicâs Shares Tumble as Updated Phase 2 Data Casts Shadows on Takedaâs Entyvio Rival
Morphic Therapeutic has encountered a setback, as more comprehensive data from its much-anticipated EMERALD-1 trial unveiled uncertainties, causing its stock ...
NICE approves Lillyâs Omvoh for ulcerative colitis after FDA rejection, citing cost-effectiveness and clinical benefits
“In a significant turn of events, Eli Lilly, despite initial setbacks in the US market with its ulcerative colitis drug ...
Acelyrinâs lead drug flops in phase 3 trial, wiping out half of its market value
Acelyrin, a biotech company based in Los Angeles, has delivered a shocking blow to its investors. Despite successfully raising an ...
Roche’s Potential $7billion Acquisition: Exploring the Purchase of Roivant’s Promising Drug
According to media reports, Roche is said to be in the final stages of negotiations with Roivant for a potential ...
Sandoz Enters US Immunology Market with Launch of High-Concentration Formulation Hyrimoz
Source – Novartis On July 1, 2023, Sandoz made an announcement regarding the availability of their biosimilar Hyrimoz (adalimumab-adaz) injection ...
Skyrizi from AbbVie wins a maintenance trial for ulcerative colitis and is poised to receive FDA approval
Source – Abbvie On 16 June 2023, Risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint ...
